<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The prevalence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (<z:chebi fb="21" ids="53713">APA</z:chebi>) in patients with immune thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo> (<z:chebi fb="0" ids="16039">ITP</z:chebi>) varies from 25 to 75% in the literature </plain></SENT>
<SENT sid="1" pm="."><plain>The risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> in this subgroup of patients is debated </plain></SENT>
<SENT sid="2" pm="."><plain>In parallel, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> is present in 22 to 42% of patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: The main study objective was to compare the profile at diagnosis of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA), anticardiolipin antibody (ACL) and anti-β(2)GP-I antibody between a cohort of 93 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="16039">ITP</z:chebi> patients and a cohort of 27 primary APS patients </plain></SENT>
<SENT sid="4" pm="."><plain>The secondary objectives were: to evaluate the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> in <z:chebi fb="0" ids="16039">ITP</z:chebi> patients depending on the presence of <z:chebi fb="21" ids="53713">APA</z:chebi>; to compare the profile of <z:chebi fb="21" ids="53713">APA</z:chebi> and to assess the occurrence of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> in APS patients depending on the presence of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In <z:chebi fb="0" ids="16039">ITP</z:chebi> patients, the prevalence of <z:chebi fb="21" ids="53713">APA</z:chebi> was 25%; association of several different <z:chebi fb="21" ids="53713">APA</z:chebi> was less frequent than in APS patients; mean titles of ACL and anti-β(2)GP-I antibodies were comparable between the two cohorts; two spontaneous venous thromboses occurred in <z:chebi fb="0" ids="16039">ITP</z:chebi> patients, with no particular profile of <z:chebi fb="21" ids="53713">APA</z:chebi> (median follow-up: 36 months) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> was present in 26% of APS patients; it was always moderate and asymptomatic, and sometimes intermittent; no particular profile of <z:chebi fb="21" ids="53713">APA</z:chebi> was associated to <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>; only one thrombocytopenic patient developed a systemic <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> and no particular profile of <z:chebi fb="21" ids="53713">APA</z:chebi> could be found associated (median follow-up: 48 months) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="16039">ITP</z:chebi> patients with <z:chebi fb="21" ids="53713">APA</z:chebi> have less frequently an association of different <z:chebi fb="21" ids="53713">APA</z:chebi> than APS patients do; their risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> appears low </plain></SENT>
</text></document>